HSBC downgraded Procter & Gamble to 'Hold' following mixed Q4 fiscal 2026 results, where earnings beat estimates but sales missed expectations. The company reported $1.43 earnings per share, slightly down from last year but above forecasts, while sales grew 2% to $21.20 billion, below the $21.40 billion estimate. Procter & Gamble's fiscal 2027 outlook is cautious, projecting modest sales growth of 1-3% and core earnings growth of 0-3%, leading to a nearly 3% drop in its stock price. Segment performance varied, with beauty sales up 6% but declines in health care and baby/family care sectors, reflecting mixed consumer demand.
Procter & Gamble's Q4 FY26 core earnings declined year-over-year, impacted by stagnant revenue and increasing costs. Despite strong profit margins and supportive stock metrics like dividends and forward price-to-earnings ratios, rising macroeconomic ...
Wall Street experienced a significant selloff with the Nasdaq 100 nearing correction territory and the Dow Jones dropping over 1,000 points, wiping out recent gains. The selloff is driven by fears of rising interest rates after three Federal Reserve ...
Procter & Gamble reported a 3% sales increase in the latest quarter despite economic pressures, highlighting that rising gas prices are causing consumers to opt for smaller pack sizes and seek promotions. The company noted a split in consumer behavio...
The FTSE 100 reached a new intraday high above 10,945, driven by strong earnings from companies like Standard Chartered, Reckitt Benckiser, and Rio Tinto, which also announced increased dividends and share buybacks. Rising oil prices, fueled by renew...
Procter & Gamble reported Q4 revenue of $21.2 billion, slightly below analyst estimates, causing shares to fall over 3%. While adjusted EPS beat expectations at $1.43, revenue growth was flat organically and net earnings declined 16%. The company exp...
